Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Sabatel, Céline ^a   Cornet, Anne M ^a   Tabruyn, Sébastien P ^a   Malvaux, Ludovic ^a   Castermans, Karolien ^a   Martial, Joseph A ^a   Struman, Ingrid ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROTEIN P21; SCLEROPROTEIN; SPROUTY PROTEIN; SPROUTY1 PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PHOSPHOPROTEIN; PROLACTIN 16 KDA FRAGMENT, HUMAN; PROLACTIN 16-KDA FRAGMENT, HUMAN; SMALL INTERFERING RNA; SPRY1 PROTEIN, HUMAN; SPRY1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL COMPARTMENTALIZATION; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CELL TRANSFORMATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXPERIMENTAL MODEL; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INDUCTION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; QUANTITATIVE ANALYSIS; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; CATTLE; CELL CULTURE; CELL MOTION; CELL STRAIN HCT116; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; WESTERN BLOTTING;

MURINAE;

ANIMALS; BLOTTING, WESTERN; CATTLE; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PROLACTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956482477     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-231     Document Type: Article

References (51)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974. 10.1038/nature04483, 16355214.
2. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26(22):3113-3121. 10.1038/sj.onc.1210394, 17496910.
3. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998, 92(2):253-263. 10.1016/S0092-8674(00)80919-8, 9458049.
4. Minowada G, Jarvis LA, Chi CL, Neubuser A, Sun X, Hacohen N, Krasnow MA, Martin GR. Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 1999, 126(20):4465-4475.
5. Mason JM, Morrison DJ, Basson MA, Licht JD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 2006, 16(1):45-54. 10.1016/j.tcb.2005.11.004, 16337795.
6. Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 2008, 11(1):53-62. 10.1007/s10456-008-9089-1, 18219583.
7. Edwin F, Anderson K, Ying C, Patel TB. Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol 2009, 76(4):679-691. 10.1124/mol.109.055848, 19570949.
8. Taniguchi K, Ishizaki T, Ayada T, Sugiyama Y, Wakabayashi Y, Sekiya T, Nakagawa R, Yoshimura A. Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth. Cancer Sci 2009, 100(9):1648-1654. 10.1111/j.1349-7006.2009.01214.x, 19493272.
9. Taniguchi K, Sasaki K, Watari K, Yasukawa H, Imaizumi T, Ayada T, Okamoto F, Ishizaki T, Kato R, Kohno R, et al. Suppression of Sproutys has a therapeutic effect for a mouse model of ischemia by enhancing angiogenesis. PLoS One 2009, 4(5):e5467. 10.1371/journal.pone.0005467, 2674940, 19424491.
10. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 1999, 96(4):1246-1251. 10.1073/pnas.96.4.1246, 15448, 9990009.
11. Nguyen NQ, Tabruyn SP, Lins L, Lion M, Cornet AM, Lair F, Rentier-Delrue F, Brasseur R, Martial JA, Struman I. Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc Natl Acad Sci USA 2006, 103(39):14319-14324. 10.1073/pnas.0606638103, 1599962, 16973751.
12. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 2003, 63(2):386-393.
13. Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16 K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 2001, 61(19):7356-7362.
14. Nguyen NQ, Cornet A, Blacher S, Tabruyn SP, Foidart JM, Noel A, Martial JA, Struman I. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16 K hPRL. Mol Ther 2007, 15(12):2094-2100. 10.1038/sj.mt.6300294, 17726458.
15. Kinet V, Nguyen NQ, Sabatel C, Blacher S, Noel A, Martial JA, Struman I. Antiangiogenic liposomal gene therapy with 16 K human prolactin efficiently reduces tumor growth. Cancer Lett 2009, 284(2):222-228. 10.1016/j.canlet.2009.04.030, 19473755.
16. Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, Martial JA, Weiner R, Struman I, Grant MB. Molecular targeting of antiangiogenic factor 16 K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 2004, 45(7):2413-2419. 10.1167/iovs.03-1001, 15223825.
17. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007, 128(3):589-600. 10.1016/j.cell.2006.12.036, 17289576.
18. Clapp C, Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 1992, 130(3):1380-1386. 10.1210/en.130.3.1380, 1311239.
19. Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI. The antiangiogenic factor 16 K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 2000, 14(10):1536-1549. 10.1210/me.14.10.1536, 11043570.
20. Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I. The antiangiogenic factor 16 K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 2003, 17(9):1815-1823. 10.1210/me.2003-0132, 12791771.
21. Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol 2005, 19(7):1932-1942. 10.1210/me.2004-0515, 15746189.
22. D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16 K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999, 13(5):692-704. 10.1210/me.13.5.692, 10319320.
23. Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, Griffioen AW, Martial JA, Struman I. The angiostatic 16 K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Mol Endocrinol 2007, 21(6):1422-1429. 10.1210/me.2007-0021, 17405903.
24. Impagnatiello MA, Weitzer S, Gannon G, Compagni A, Cotten M, Christofori G. Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol 2001, 152(5):1087-1098. 10.1083/jcb.152.5.1087, 2198812, 11238463.
25. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 2004, 299(2):286-293. 10.1016/j.yexcr.2004.06.014, 15350528.
26. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004, 78(8):4108-4119. 10.1128/JVI.78.8.4108-4119.2004, 374271, 15047827.
27. Gross I, Bassit B, Benezra M, Licht JD. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem 2001, 276(49):46460-46468. 10.1074/jbc.M108234200, 11585837.
28. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26(22):3227-3239. 10.1038/sj.onc.1210414, 17496918.
29. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36(3):131-149. 10.1046/j.1365-2184.2003.00266.x, 12814430.
30. Cheng T. Cell cycle inhibitors in normal and tumor stem cells. Oncogene 2004, 23(43):7256-7266. 10.1038/sj.onc.1207945, 15378085.
31. Ho PY, Hsu SP, Liang YC, Kuo ML, Ho YS, Lee WS. Inhibition of the ERK phosphorylation plays a role in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells. Toxicol Appl Pharmacol 2008, 229(1):86-93. 10.1016/j.taap.2007.12.028, 18272192.
32. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998, 140(5):1255-1263. 10.1083/jcb.140.5.1255, 2132684, 9490736.
33. Lee SH, Schloss DJ, Jarvis L, Krasnow MA, Swain JL. Inhibition of angiogenesis by a mouse sprouty protein. J Biol Chem 2001, 276(6):4128-4133. 10.1074/jbc.M006922200, 11053436.
34. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G, Ittmann M. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004, 64(14):4728-4735. 10.1158/0008-5472.CAN-03-3759, 15256439.
35. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, et al. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004, 64(17):6127-6136. 10.1158/0008-5472.CAN-04-1207, 15342396.
36. Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. Faseb J 2006, 20(7):1009-1011. 10.1096/fj.05-4880fje, 16571776.
37. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG, Bizekis C, Galloway AC, Basilico C, Mignatti P. Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. Faseb J 2002, 16(6):598-600.
38. Yigzaw Y, Cartin L, Pierre S, Scholich K, Patel TB. The C terminus of sprouty is important for modulation of cellular migration and proliferation. J Biol Chem 2001, 276(25):22742-22747. 10.1074/jbc.M100123200, 11279012.
39. Poppleton HM, Edwin F, Jaggar L, Ray R, Johnson LR, Patel TB. Sprouty regulates cell migration by inhibiting the activation of Rac1 GTPase. Biochem Biophys Res Commun 2004, 323(1):98-103. 10.1016/j.bbrc.2004.08.070, 15351707.
40. Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, Cheng SL. Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 2001, 276(17):14443-14450.
41. Jin A, Kurosu T, Tsuji K, Mizuchi D, Arai A, Fujita H, Hattori M, Minato N, Miura O. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. Oncogene 2006, 25(31):4332-4340. 10.1038/sj.onc.1209459, 16518411.
42. Edwin F, Patel TB. A novel role of Sprouty 2 in regulating cellular apoptosis. J Biol Chem 2008, 283(6):3181-3190. 10.1074/jbc.M706567200, 2527238, 18070883.
43. Lito P, Mets BD, Appledorn DM, Maher VM, McCormick JJ. Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. J Biol Chem 2009, 284(2):848-854. 10.1074/jbc.M808045200, 2613613, 19008219.
44. Gross I, Armant O, Benosman S, de Aguilar JL, Freund JN, Kedinger M, Licht JD, Gaiddon C, Loeffler JP. Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death Differ 2007, 14(10):1802-1812. 10.1038/sj.cdd.4402188, 17599098.
45. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999, 247(2):495-504. 10.1006/excr.1998.4359, 10066377.
46. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996, 271(34):20608-20616. 10.1074/jbc.271.34.20608, 8702807.
47. Beier F, Taylor AC, LuValle P. The Raf-1/MEK/ERK pathway regulates the expression of the p21(Cip1/Waf1) gene in chondrocytes. J Biol Chem 1999, 274(42):30273-30279. 10.1074/jbc.274.42.30273, 10514521.
48. Han S, Sidell N, Roman J. Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett 2005, 219(1):71-81. 10.1016/j.canlet.2004.07.040, 15694666.
49. Gospodarowicz D, Massoglia S, Cheng J, Fujii DK. Effect of fibroblast growth factor and lipoproteins on the proliferation of endothelial cells derived from bovine adrenal cortex, brain cortex, and corpus luteum capillaries. J Cell Physiol 1986, 127(1):121-136. 10.1002/jcp.1041270116, 3958059.
50. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 2004, 64(10):3586-3592. 10.1158/0008-5472.CAN-03-2673, 15150116.
51. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.